Cue Biopharma, Inc. (CUE) Insider Trading & SEC Filings
Last SEC filing
Cue Biopharma, Inc. (CUE) has filed 13 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-30. Insiders disclosed 2 open-market purchases totaling $1000K. 9 Form 8-K material event filings were reported by CUE in the last 90 days. InsiderAlpha tracks every CUE SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. trades under the ticker CUE. InsiderAlpha tracks 30 primary SEC Form 4 filings from 17 reporting insiders for CUE since 2024, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
| SEC CIK | 0001645460 |
90-Day SEC Filing Activity
| Insider purchases (90d) | 2 ($1000K) |
|---|---|
| Form 4 filings (90d) | 13 |
| Form 8-K filings (90d) | 9 |
| Latest Form 4 filing | 2026-07-30 |
Recent CUE Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dominique Christian Borie | Chief Medical Officer | A - Grant or award | 31.5K | $0.00 | - | SEC | |
| Michael Vincent Meluzio | VP, Prin. Accounting Officer | A - Grant or award | 40.9K | $0.00 | - | SEC | |
| Sumita Ray | Chief Legal Compliance Officer | A - Grant or award | 54.6K | $0.00 | - | SEC | |
| Shao-Lee Lin | Chief Executive Officer | A - Grant or award | 327.5K | $0.00 | - | SEC | |
| Pamela Garzone | Insider | A - Grant or award | 21.8K | $0.00 | - | SEC | |
| Daniel A. Camardo | Insider | A - Grant or award | 21.8K | $0.00 | - | SEC | |
| Pasha Sarraf | Insider | A - Grant or award | 21.8K | $0.00 | - | SEC | |
| Viola Mong Meehan | Insider | A - Grant or award | 21.8K | $0.00 | - | SEC | |
| Shao-Lee Lin | CHIEF EXECUTIVE OFFICER | A - Grant or award | 327.5K | $0.00 | - | SEC | |
| Pasha Sarraf | Insider | P - Open-market purchase | 4.2K | $0.31 | $1K | SEC | |
| Pasha Sarraf | Insider | P - Open-market purchase | 77.1K | $0.30 | $23K | SEC | |
| Pasha Sarraf | Insider | P - Open-market purchase | 86.9K | $0.32 | $28K | SEC | |
| Pasha Sarraf | Insider | P - Open-market purchase | 78.1K | $0.31 | $24K | SEC | |
| Pasha Sarraf | Insider | P - Open-market purchase | 77.4K | $0.30 | $23K | SEC | |
| Daniel R. Passeri | CHIEF EXECUTIVE OFFICER | P - Open-market purchase | 30.0K | $1.03 | $31K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Cue Biopharma, Inc. (CUE). Updated in real time as new filings are submitted to the SEC.
Most-Active CUE Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Shao-Lee Lin | 8 | $2.00M |
| Dominique Christian Borie | 2 | - |
| Sumita Ray | 2 | - |
| Michael Vincent Meluzio | 2 | - |
| Viola Mong Meehan | 2 | - |
Recent CUE Form 8-K Material Events
- - Item 5.02 [SEC]
- - Item 1.01, 3.02, 5.02, 8.01, 9.01 [SEC]
- - Item 5.02, 5.07, 9.01 [SEC]
- - Item 5.02, 8.01 [SEC]
- - Item 9.01 [SEC]
Recent Insider Filings
- - Shao-Lee Lin (Chief Executive Officer)
- - Dominique Christian Borie (Chief Medical Officer)
- - Pamela Garzone (Insider)
- - Daniel A. Camardo (Insider)
- - Pasha Sarraf (Insider)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in CUE insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
CUE Insider Trading - FAQ
- What is the latest insider trade for CUE?
- Cue Biopharma, Inc. (CUE) had 13 insider filings in the last 90 days, with the most recent on 2026-07-30. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying CUE stock?
- 2 insider purchases of CUE were filed in the last 90 days, totaling $1000K.
- How many insiders are selling CUE stock?
- 0 insider sales of CUE were filed in the last 90 days.
- Where can I see CUE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks CUE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $CV CapsoVision, Inc
- $CVKD Cadrenal Therapeutics, Inc.
- $CVM CEL SCI CORP
- $DMAC DiaMedica Therapeutics Inc.
- $EDGM Edgemode, Inc.
- $ERNA Ernexa Therapeutics Inc.
- $ETNB 89bio, Inc.
- $EWTX Edgewise Therapeutics, Inc.
- $FBIO Fortress Biotech, Inc.
- $GNPX Genprex, Inc.
Related Companies - Recent Insider Activity
- UNITED THERAPEUTICS Corp (UTHR)
- Liquidia Corp (LQDA)
- BeOne Medicines Ltd. (ONC)
- PERRIGO Co plc (PRGO)
- Processa Pharmaceuticals, Inc. (PCSA)
- Nuvalent, Inc. (NUVL)
- CYTOKINETICS INC (CYTK)
- Elanco Animal Health Inc (ELAN)
- Avalo Therapeutics, Inc. (AVTX)
- NATURES SUNSHINE PRODUCTS INC (NATR)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live CUE dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.